Tarantino, Umberto
Cariati, Ida
Greggi, Chiara
Iundusi, Riccardo
Gasbarra, Elena
Iolascon, Giovanni
Kurth, Andreas
Akesson, Kristina E.
Bouxsein, Mary
Tranquilli Leali, Paolo
Civinini, Roberto
Falez, Francesco
Brandi, Maria Luisa http://orcid.org/0000-0002-8741-0592
Article History
Received: 3 November 2021
Accepted: 23 June 2022
First Online: 18 July 2022
Declarations
:
: K-E. Akesson reports consultations and lecture fees from Amgen, Astellas Pharma, Chugai, RenaPharma, and UCB. M. Bouxsein serves on the Advisory Board for Keros Therapeutics and Beryl Health. M-L. Brandi has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, and UCB; reports grants and/or speaker for Abiogen, AgNovosAlexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, and UCB; and reports consultations for Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, and UCB. I. Cariati has no disclosures. R. Civinini reports personal fees and consultancy or lecture fees from Orthofix, Smith &Nephew, and Microport. F. Falez reports consultations for Lima, Microport, Adler, G21, and external collaborations for Menarini. E. Gasbarra has no disclosures. C. Greggi has no disclosures. G. Iolascon serves on the Advisory Board for UCB pharma, AMGEN, Eli-Lilly. R. Iundusi has no disclosures. A. Kurth serves on the advisory board for UCB, Amgen, and AgNovos; speaker fees from Amgen, Alexion, UCB, Eli-Lilly, Theramex, Ratiopharm, and AgNovos. P. Tranquilli Leali has no disclosures. U. Tarantino serves on the Advisory Board for Abiogen, AMGEN, Eli-Lilly.